11282-Lymphomas-Non-Hodgkins-56

Lymphomas

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Non-Hodgkins
USOR Number:

  • Address

4715 Arapahoe Avenue
Boulder, CO 80303
P: (303) 385-2068

Search by practice name, trial titles, indicators and specific disease types.